Endothelin-1 and Gastrointestinal Bleeding: A Predictor for Clinical Outcomes
Given its broad role in cardiovascular diseases, ET-1 and its receptors are therapeutic targets. Endothelin receptor antagonists, such as bosentan and ambrisentan, have been developed to treat PAH and other cardiovascular disorders, underscoring ET-1’s significance in disease mechanisms and treatment strategies
Authors
- Muhammed Fatih Tütüncü (ORCID: https://orcid.org/0000-0001-8375-6265)
- Hakan Barış Demirbaş (ORCID: https://orcid.org/0000-0001-9221-3692)
- Bahaeddin Onur (ORCID: https://orcid.org/0009-0008-0174-5801)
Institutions
- Primary Health Care (QA)
Publication Details
- Journal
- Eurasian Journal of Critical Care
- Published
- 2024-12-30
- DOI
- https://doi.org/10.55994/ejcc.1550651
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00